对高血压患者内皮功能影响的运动干预:系统性审查和元分析
Chao Liang1, Zhenpeng Song1, XiaoZhi Yao2
1Department of Martial Arts, Wuhan Sports University, Wuhan, Hubei Province, China.
概括
运动通过增加氧化 (NO) 和流媒扩张 (FMD) 来显著改善高血压患者的内皮功能,同时减少内皮蛋白-1 (ET-1). 高强度有氧运动对NO是最佳的,适度的抵抗运动对ET-1是最佳的.
科学领域:
- 心血管研究研究心血管研究
- 运动生理学 运动生理学
- 高血压管理 高血压管理
背景情况:
- 内皮功能障碍是高血压发展的关键因素.
- 运动对高血压患者内皮功能的影响仍在争论中.
- 了解最佳的运动方案对于治疗干预至关重要.
研究的目的:
- 评估运动对高血压患者内皮功能干预效应.
- 确定特定的炼方案,使内皮功能得到更大的改善.
- 分析运动对氧化 (NO),内甲素-1 (ET-1) 和流媒体扩张 (FMD) 的影响.
主要方法:
- 对37项涉及2801名参与者的研究进行了元分析.
- 评估了干预措施对运动对内皮功能标志物的影响.
- 亚组分析探讨了不同强度,持续时间和频率的运动有效性.
主要成果:
- 运动显著改善了内源性氧化 (NO) 水平 (SMD = 0.89) 和流媒体扩张 (FMD) (SMD = -0.57).
- 运动显著降低了内甲素-1 (ET-1) 水平 (SMD = -0.94).
- 高强度有氧运动 (35-50分钟,3-4次/周,10-12周) 对NO的影响最大.
- 中等强度的抵抗运动 (≥60分钟,每周6次,15-18周) 对ET-1表现出最大的影响.
结论:
- 运动在改善高血压患者内皮功能方面是有效的.
- 运动可以提高NO和口热的水平,同时降低ET-1分泌.
- 特定的运动处方,如高强度有氧或中度抵抗训练,可以优化高血压管理的治疗结果.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
Antihypertensive Drugs: Vasodilators
508
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
508
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
620
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
620


